Objective: To evaluate the efficacy, safety and tolerability of taranabant in obese and overweight patients. Design: Double-blind, randomized, placebo-controlled study. Subjects: Patients were X18 years old, with body mass index of 27-43 kg m -2 , and 51% with metabolic syndrome (MS) randomized to placebo (N ¼ 417) or taranabant 2 mg (N ¼ 414), 4 mg (N ¼ 415) or 6 mg (N ¼ 1256) for 104 weeks. Measurements: Key efficacy measurements included body weight, waist circumference (WC), lipid and glycemic end points. Results: On the basis of risk/benefit assessments, the 6-mg dose was discontinued during year 1 (patients on 6 mg were downdosed to 2 mg or placebo) and the 4-mg dose was discontinued during year 2 (patients on 4 mg were down-dosed to 2 mg). Changes from baseline in body weight at week 52 (all-patients-treated population, last observation carried forward analysis) were À2.6, À6.6 and À8.1 kg, respectively, for placebo and taranabant 2 and 4 mg (both doses Po0.001 vs placebo). For patients who completed year 1, changes from baseline in body weight at week 104 were À1.4, À6.4 and À7.6 kg for placebo and taranabant 2 and 4 mg, respectively (both doses Po0.001 vs placebo). The proportions of patients at weeks 52 and 104 who lost at least 5 and 10% of their baseline body weight were significantly higher and the proportions of patients who met criteria for MS were significantly lower for taranabant 2 and 4 mg vs placebo. The incidence of adverse experiences classified in the gastrointestinal, nervous, psychiatric, cutaneous and vascular organ systems were generally observed to be dose related with taranabant vs placebo. Conclusion: Taranabant at the 2-and 4-mg dose was effective in achieving clinically significant weight loss over 2 years and was associated with dose-related increases in adverse experiences. On the basis of these and other data, an assessment was made that the overall safety and efficacy profile of taranabant did not support its further development for the treatment of obesity.
Introduction
Although the cornerstone for the treatment of obesity and overweight is dietary restriction and exercise, most randomized weight loss trials of lifestyle and behavioral interventions report modest weight loss and high recidivism. [1] [2] Currently marketed weight loss medications, which target neurotransmitters or gut lipases, have limited efficacy and a variety of safety and tolerability issues. 3 Safe and effective pharmacological therapy as an adjunct to diet and exercise for the treatment of obese and overweight patients would serve an unmet medical need. In recent years the endocannabinoid pathway has been the focus of intensive efforts toward antiobesity drug development. Endocannabinoids are believed to promote appetite and food intake by activating cannabinoid-1 receptors (CB1Rs) expressed in hypothalamic centers that regulate energy balance, the limbic system that regulates reward pathways, and other cortical and subcortical regions. 4, 5 In addition, CB1R have been detected in several peripheral tissues, [6] [7] [8] [9] although the functional significance of its expression in those tissues remains to be established. Taranabant (MK-0364) is a highly specific CB1R inverse agonist 10 that was being developed for the treatment of obesity. Studies in humans indicate that taranabant affects body weight by reducing appetite and increasing energy expenditure. 11 This manuscript presents data from one of the phase III studies that were part of the taranabant development program. Results from this and other studies were used to make a composite risk/benefit assessment of taranabant, which led to its discontinuation from clinical development for the treatment of obesity. Dose selection for this study was guided by the results of a 12-week phase II study, 11 which explored the efficacy, safety and tolerability of taranabant at a daily dose of 0.5, 2, 4 or 6 mg. Results of that study suggested that treatment with doses of 4-mg and 6-mg taranabant (referred to as 'high-dose taranabant') led to greater weight loss efficacy compared with 2-mg taranabant and was associated with an acceptable safety profile.
Materials and methods

Experimental design
This was a 2-year, double-blind, randomized, placebo-controlled study (taranabant Protocol 015) that involved 122 international sites. After a 1-week screening period and a 2-week single-blind placebo plus diet/exercise run-in period, patients were randomized in a 2:2:2:3:3 ratio to placebo, taranabant 2, 4 and 6 mg (fixed) or 6 mg (up-titrated from 2 mg at 2-week intervals), respectively, administered once daily for 104 weeks. The objective of the titration scheme was to assess whether initial up-titration would reduce the occurrence of gastrointestinal-related adverse experiences, which were observed in the phase II study. The study also included a 28-day post-treatment follow-up period. In addition, patients who were discontinued from study drug were asked to continue in the study even though they were off the study drug. This off-study drug phase of the study was instituted during year 1 for the purpose of enhancing collection of long-term safety data. The study was monitored by an independent external Data Safety Monitoring Committee, which reviewed unblinded safety and efficacy data across the taranabant phase III program. As initially designed, patients were to remain on their originally assigned doses throughout the course of the study. However, two changes in the doses of taranabant were made during the conduct of the study. At a routine meeting in year 1, the Data Safety Monitoring Committee recommended discontinuation of the 6-mg dose based on its minimal increase in efficacy over 4 mg and a trend toward a higher incidence of adverse experiences. The Committee did not conclude that the 6-mg dose needed to be immediately halted and patients on the 6-mg dose (fixed and titrated arms) were randomly down-dosed (1:2) to treatment with placebo or taranabant 2 mg, respectively ( Figure 1 ). Full implementation of the 6 mg down-dosing took approximately 6 months because of the time required for regulatory agency and ethics board approvals in multiple countries. Only 14 patients originally allocated to the 6-mg dose were down-dosed before the end of year 1; the remainder of this group was down-dosed within the initial 3 months of year 2. During year 2, a decision was made to discontinue the 4-mg dose (not depicted in Figure 1 ) because of a re-assessment of the risk/benefit profile of this dose based on accumulating data. All patients originally allocated to the 4 mg dose were down-dosed to the 2-mg dose. Only two patients were downdosed from taranabant 4 to 2 mg before the end of year 2. The remainder of this group was to be down-dosed during a separate extension study that followed year 2 (not depicted in Figure 1 ).
The diet regimen used in this study consisted of a recommended diet, which targeted 25% caloric restriction. The exercise regimen was designed according to the patient's current level of physical activity and health status. Details of dietary counseling are presented in Supplementary Information.
Subjects
Eligible patients were X18 years of age, with a body mass index between 30 and 43 kg m -2 (inclusive). Patients with a body mass index between 27 and 30 kg m -2 (inclusive) were eligible if they had previously been diagnosed with the obesity-related comorbidity of hypertension, dyslipidemia or sleep apnea. In addition, all patients had to meet at least one of the following four criteria at screening: (1) triglyceride (TG) levels X150 mg per 100 ml; (2) high-density lipoprotein cholesterol (HDL-C) levels o40 mg per 100 ml in men and o50 mg per 100 ml in women; (3) seated systolic blood pressure (BP) X130 mm Hg or seated diastolic BP X85 mm Hg; (4) impaired fasting plasma glucose (X100 mg per 100 ml and o126 mg per 100 ml). These latter criteria, which are elements of the metabolic syndrome (MS), were included to ensure enrollment of at least 50% of patients with the MS. In the study, patient were classified as having the MS if they had at least three of the following five criteria: (1) waist circumference (WC) X102 cm for men and X88 cm for women (2) TG X150 mg per 100 ml; (3) HDL-C o40 mg per 100 ml for men or o50 mg per 100 ml for women; (4) seated systolic BP X130 mm Hg or seated diastolic BP X85 mm Hg; and (5) impaired fasting glucose (X100 mg per 100 ml and o126 mg per 100 ml.
Patients had to be compliant with diet and exercise as measured by demonstration of no weight gain during the run-in period.
Patients with a history of a major psychiatric disorder were excluded from the study. However, patients with a history of mild depression who were asymptomatic at the time of screening/randomization, including those who were on a single medication for the treatment of their depression, were allowed to participate. To assist investigators with assessment of depressive symptomatology, the Patient Health 12 was incorporated into the study shortly after enrollment had begun. Because of this timing, not all patients were screened using the High-dose taranabant LJ Aronne et al PHQ-9. Other exclusion criteria included diabetes mellitus; significant cardiovascular, hepatic, gastrointestinal, neurological, pulmonary or renal disease; use of nicotine-containing products; substance abuse; and use of a moderate or potent CYP3A4 inhibitor. 13 On the basis of the occurrence of a few seizures reported during the phase III program, a protocol amendment during year 1 discontinued patients with a history of seizures or those who were at a high risk for developing seizures. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study was approved by an institutional review board or independent ethics committee and all patients provided written informed consent.
Measurements
The primary efficacy end points were the change in body weight from baseline (last measurement before start of double-blind study drug) and the proportion of patients who lost at least 5 or 10% of their baseline body weight at week 52. As a result of the decision to down-dose the 6 mg group to 2 mg or placebo during year 1, the statistical analysis in the amended protocol did not include the 6 mg dose in the primary efficacy analysis at week 52. As it was anticipated that only a limited number of patients would be down-dosed from taranabant 4 to 2 mg before the end of year 2, the statistical analysis plan for the efficacy analysis of the 4-mg dose at week 104 was not altered.
Key secondary end points at week 52 included change from baseline in WC, lipid end points (TG, HDL-C, non-HDL-C and LDL-C), measures of glycemic control (fasting serum insulin, insulin sensitivity determined by QUICKI (quantitative insulin sensitivity check index) 14 and fasting plasma glucose), and the proportion of patients who met criteria for MS. Other secondary end points assessed at week 52 included change from baseline in systolic BP and diastolic BP and patientreported outcomes, including the Short Form 36 Health Survey Version 2 Acute Form (SF-36v2 Acute), 15 The Impact of Weight on Quality of Life (IWQoL) 16 and the EuroQoL (EQ5D) Health State Assessment. 17 Measurements of percent body fat (measured by dual-energy X-ray absorptiometry in a sub-population of patients in the United States), highsensitivity C-reactive protein and adiponectin were not obtained after week 24 because the subsequent down-dosing would confound the continued longitudinal analysis of these measures. Safety assessments included collection of adverse experiences, physical examinations, vital signs and selfadministered questionnaires for the evaluation of cognitive/ neuropsychomotor performance (Digital Symbol Substitution Test (DSST) 18 ), mood (Profile of Mood States brief form (POMSb) 19 ) and depressive symptomatology (PHQ-9).
If a patient reported a psychiatric adverse experience, a full Patient Health Questionnaire (FPHQ) 20 was administered.
Adjudication of possibly suicide-related adverse events was performed according to the Food and Drug Administration guidance for exploring suicidality (suicidal ideation and behavior) in placebo-controlled clinical trials. 21 Narratives for possibly suicide-related adverse events were written and adjudication of these events was performed by an independent external adjudication committee, which used the High-dose taranabant LJ Aronne et al Columbia Classification Algorithm of Suicide Assessment (C-CASA).
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Laboratory assays Details of laboratory assays are presented in Supplementary Information.
Statistical methodology
The primary analysis population was an all-patients-treated population, which included all randomized patients who had a baseline value, had received at least one dose of randomized treatment and had at least one post-baseline measurement. The primary efficacy end point, mean change from baseline in body weight at week 52, was assessed by comparing the placebo group to taranabant 2 and 4 mg groups using an analysis of covariance (ANCOVA). The model included terms for treatment, baseline body weight, weight change during run-in and region (US and four ex-US geographic regions). The proportion of patients with at least 5% weight loss from baseline (5% responders) and 10% weight loss from baseline (10% responders) at week 52 were assessed using a logistic model with terms for treatment, baseline body weight, weight change during run-in and region. Secondary end points were analyzed using an ANCOVA model with terms for treatment, baseline value of measure, weight change during the run-in period, change in the measure during run-in, baseline body weight and region. The proportion of patients who had MS at week 52 was assessed by comparing taranabant 2 mg and 4 mg with placebo using a logistic model.
The primary and secondary end points at week 104 in patients who completed week 52 and had at least one efficacy measurement taken after week 52 were assessed using the above-mentioned ANCOVA models. The comparison of body weight regain from the time of down-dose to 52 weeks after dose change in patients who had been on taranabant 6 mg during year 1 and who had been down-dosed to placebo or 2 mg was performed using ANCOVA, with factors of treatment, region, body weight change while on 6 mg and body weight at the time of down-dose as covariates.
All randomized patients who received at least one dose of active treatment were included in the safety assessment. Inferential P-values were obtained from analyses of prespecified clinical adverse experiences. For these analyses, comparisons based on differences in proportions of patients with an event were performed using Fisher's exact test and confidence intervals (CIs) for the between-group differences were computed using Wilson's score method. Changes from baseline in questionnaire scores were assessed using ANCOVA models with terms for treatment, baseline body weight, weight change during the run-in, baseline score and region.
CB1R antagonists have been reported to have weightindependent effects on glycemic and lipid parameters. To assess taranabant for such effects, the weight-independent portion of the total treatment effect was calculated as the ratio of the weight-adjusted treatment effect to the treatment effect in the ANCOVA model without weight change at week 52 as a covariate.
An analysis of year 1 data was performed after the 52-week time point. An analysis of the year 2 data was performed after the 104-week time point.
Results
Baseline characteristics and patient disposition A total of 2502 patients were randomized, and 1177 (47%) completed the study ( Supplementary Information, Table S1 ). Of the total, 41% were male and 51% met criteria for the MS.
A total of 1325 (53%) patients discontinued study drug before completion of the 2-year study. The incidence of discontinuations due to clinical adverse experiences was greater in the taranabant groups compared with the placebo group. The primary reasons for study discontinuation are listed in Supplementary Table S1 . In all, 260 (10%) of the patients who discontinued from the study agreed to continue in the off-study drug phase of the study. The treatment groups were similar with respect to patient demographics and baseline characteristics (Table 1) .
In the following description of the efficacy and safety results, taranabant groups are compared with the placebo group. There were no formal analyses of differences between taranabant groups. In describing results, the terms 'numerically higher' or 'numerically lower' are used to denote differences from placebo that are not statistically significant but that might be clinically meaningful. The incidences of adverse experiences in the taranabant fixed and titrated 6 mg groups were similar and, therefore, for simplicity of presentation, adverse experiences in the 6 mg fixed and titrated groups were combined.
Efficacy results
Treatment with taranabant 2 and 4 mg led to significantly greater weight loss from baseline at weeks 52 and 104 (Table 2 and Figures 2a and 3) . Although the taranabant 6 mg groups (fixed and titrated) were not included in the predefined efficacy analysis, the change in body weight of the combined 6 mg fixed and titrated groups is shown in Figure 2b , which plots the weight loss of all treatment groups using all observed data for the within-treatment change in body weight at week 52. The mean observed changes from baseline at week 52 in body weight were À4.1, À8.8, À10.3 and À11.5 kg in the placebo and in 2-, 4-and 6-mg (fixed þ titrated) groups, respectively.
Treatment with taranabant 2 and 4 mg also led to significantly greater reductions from baseline in WC at weeks 52 and 104 (Table 2) . Consistent with these observations, there were significant reductions from baseline in percent body fat, as assessed using dual-energy X-ray absorptiometry, from baseline at week 24 in the taranabant 2-and 4-mg groups ( Table 2) .
The proportions of patients achieving at least 5% and at least 10% of loss of baseline body weight at weeks 52 and 104 were significantly greater in the 2-and 4-mg groups ( Figure 4 ).
Patients allocated to treatment with taranabant 6 mg during year 1 and who had been down-dosed to taranabant 2 mg had significantly less weight regain than those downdosed to placebo (the least-squares mean weight regain in patients who were down-dosed to placebo and taranabant 2 mg was 5.3 (95% CI 4.8-5.7) and 3.0 (95% CI 2.6-3.3) kg, respectively; Figure 5 ).
The proportion of patients who met criteria for MS at weeks 52 and 104 was significantly lower in the taranabant 2-and 4-mg groups (Supplementary Table S2 ).
Treatment with taranabant 2 and 4 mg produced significant median percentage reductions from baseline in TG and mean percentage increases in HDL-C at weeks 52 and 104 (Table 2) . A small (À3.3%), significant mean percentage reduction in LDL-C was observed with taranabant 4 mg at week 52, whereas no significant differences in mean percentage change in LDL-C were observed in the taranabant 2-mg group at week 52 or in the 2-and 4-mg groups at week 104 (Table 2) .
Decreases in fasting serum insulin were observed after 52 weeks of treatment with 2-or 4-mg taranabant; however, the decrease was significant only for the 4-mg dose (Table 2) . Treatment with taranabant had no significant effects on fasting plasma glucose at weeks 52 or 104 or on fasting serum insulin at weeks 104 (Table 2 ). Improvements in insulin sensitivity at week 52 were observed in patients treated with taranabant 2 and 4 mg with significant improvements in patients treated with 4 mg ( Table 2) .
There was a small mean reduction from baseline in systolic BP and diastolic BP at weeks 52 and 104 in the 2-and 4-mg groups (Table 2 ). There was a reduction at week 24 in highsensitivity C-reactive protein and increase in adiponectin in the 2-and 4-mg groups (Table 2) .
Secondary end points that were determined to be statistically different from placebo were subjected to an exploratory analysis to determine what percentage of the total treatment effect was due to a weight-independent effect. After adjusting for change in body weight, there were significant effects on HDL-C and QUICKI with 2-and 4-mg taranabant compared with placebo (Supplementary Table S3 ). By this Abbreviations: BMI, body mass index; BW, body weight; DBP, diastolic blood pressure; FPG, fasting plasma glucose; FSI, fasting serum insulin; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; QUICKI, quantitative insulin sensitivity check index; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; WC, waist circumference.
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analysis, approximately 50% of the HDL-C changes and approximately 70% of the QUICKI changes were estimated to be weight independent. At week 52, treatment with taranabant 4 mg led to a worsening from baseline in four components of the SF36v2 questionnaire: standardized mental component, social functioning, role emotional and mental health (Supplementary Table S4 ). No changes in the SF36v2 component scores from baseline at week 52 were observed in the taranabant 2 mg group.
At week 52, treatment with taranabant 4 mg led to an improvement from baseline in the physical function score and total score of the IWQoL (Supplementary Table S5 ). At week 52, the treatment with taranabant 2 and 4 mg led to an improvement from baseline in the self-esteem score. At week 52, the EQ5D showed improvements in all treatment groups (Supplementary Table S6) .
No difference in patient-reported outcomes between patients treated with taranabant 2 mg and those treated with placebo were observed after 104 weeks of treatment; however, a worsening was observed between the 4 mg and placebo groups in the Standardized Mental Component, 
Safety results
The overall incidences of clinical adverse experiences were comparable across the treatment groups in both years 1 and 2, although discontinuations due to overall and drug-related clinical adverse experiences were numerically higher in the taranabant groups in both years (Table 3) .
Clinical adverse experiences classified according to the Medical Dictionary for Regulatory Activities (MedDRA, version 10.1) system organ classes (SOC) are presented in Table 4 . The specific clinical adverse experiences listed that were prespecified as clinical adverse experiences related to the mechanism of action and previously observed safety profile of taranabant are discussed below. Discontinuations due to drug-related clinical adverse experiences reported by at least two patients in any treatment group in years 1 or 2 are presented in Supplementary Table S7 .
Analyses of the prespecified clinical adverse experiences in year 1 for the entire study population and in year 2 for those patients who completed year 1 and entered year 2 on the same treatment are provided in Table 5 . During year 1, the incidences of nausea and diarrhea were significantly higher in all taranabant groups; the incidences of frequent bowel movements were numerically higher in the 2 and 6-mg groups and significantly higher in the 4-mg group and the incidence of vomiting was numerically higher in the 2-mg group and significantly higher in the 4-and 6-mg groups. There were no clinically meaningful differences between the taranabant fixed and titrated 6-mg groups (data not shown) in the incidences of overall adverse experiences in the Gastrointestinal Disorders SOC or of prespecified, selected gastrointestinal-related adverse experiences, indicating that dose titration at initiation of treatment did not reduce the incidences of these adverse experiences.
In the Nervous System Disorders SOC the incidences of adverse experiences in the dizziness, sedation and syncope Figure 5 Mean change in body weight from baseline over 52 weeks after switching from 6 to 2 mg taranabant or placebo or placebo to placebo for patients who completed year 1 and entered year 2 using the last observation carried forward method in year 2. Determined by the study investigator to be possibly, probably or definitely treatment related.
d A 66-year-old man (placebo group) who died of metastatic lung cancer (investigator assessment as probably not drug related). A 56-year-old man (2-mg group) who died of septic shock secondary to necrotizing fasciitis (investigator assessment as probably not drug related). In addition, a 65-year-old female (6/2-mg group), who had been participating in the off-drug phase of the study for 167 days, died of a sudden cardiac death (investigator assessment as definitely not drug related). High-dose taranabant LJ Aronne et al groupings in the taranabant 4-mg group and in the dizziness and motor disorder groupings in the 6-mg group were significantly higher during year 1. No significant differences in the incidences of adverse experiences in Nervous System Disorders SOC groupings were observed during year 2. Two seizures occurred in the study: one in a patient in the 2-mg group who was found to have a newly diagnosed brain tumor and one in a patient in the 6 mg group who had a history of brain surgery as a child for a neuroma.
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The incidences of adverse experiences within the Psychiatric Disorders SOC plus irritability were significantly higher in year 1 and numerically higher in year 2 in all taranabant groups. The incidences of adverse experiences in the altered affect grouping and depression grouping and the adverse experience of anxiety were numerically higher in the 2 mg group and significantly higher in the 4-and 6-mg groups in year 1. The incidence of the combined adverse experiences of depressed mood and depressive symptoms were numerically higher in the 2-and 4-mg groups and significantly higher in the 6-mg groups compared with the placebo group in year 1. The incidence of the combined adverse experiences of aggression and anger were numerically higher in the taranabant groups in years 1 and 2.
Suicidal ideation was reported in three patients in the taranabant 6-mg group in year 1 and in one patient in the 4-mg group in year 2. There was one suicide attempt reported in a patient with a previous history of suicide attempts in the 6/2-mg group while the patient was receiving 2-mg, and one episode of suicidal behavior reported in a patient in the 6/2-mg group while the patient was receiving 6-mg. There were no completed suicides.
The adjudication of possibly suicide-related adverse experiences during years 1 and 2 indicated an increased incidence of suicidality in the taranabant groups (13/417 (3.1%), 22/414 (5.3%), 27/415 (6.5%), 55/1256 (4.4%) of patients in the placebo, 2-, 4-and 6-mg groups, respectively). The odds ratios for suicidality among taranabant groups were for the 2-, 4-and 6-mg (fixed and titrated) groups, respectively. This increase in suicidality in the taranabant groups primarily reflects patient-positive responses to PHQ-9 question 9 and FPHQ question 2i, which were adjudicated as representing suicidal ideation. Each question asks the patient whether they have been bothered by 'Thoughts that you would be better off dead or of hurting yourself in some way'.
The incidences of adverse experiences in the Skin and Subcutaneous Disorders SOC minus hypoesthesia facial were numerically higher in the taranabant 2-and 4-mg groups and significantly higher in the 6-mg group compared with the placebo group in year 1, which reflected the increased incidences of the adverse experiences of hyperhidrosis and pruritus.
The incidences of adverse experiences in the Vascular Disorders SOC were numerically higher in the 2-mg group Determined by the study investigator to be possibly, probably or definitely treatment related. Adverse experiences (irrespective of investigator assessed causality) reaching an incidence of at least 5% and drug-related d adverse experiences reaching an incidence of at least 2% in any treatment group in year 1 (week 52) and year 2 (weeks 52 to 104)
High-dose taranabant LJ Aronne et al Table 5 Number (%) of patients with pre-specified clinical adverse experiences and groupings of interest at year 1 (week 52) and year 2 (week 104)
Clinical adverse event High-dose taranabant LJ Aronne et al and significantly higher in the 4-and 6-mg groups compared with the placebo group in year 1, which reflected the increased incidences of the combined adverse experiences of flushing and hot flush. All treatment groups experienced improvements in DSST scores from baseline at weeks 52 and 104. The increases in the taranabant groups were smaller compared with the placebo group at week 52. No significant changes from baseline were observed in cognitive/neuropsychomotor performance (DSST) at weeks 52 and 104 in any taranabant group (Supplementary Table S8) .
No significant changes from baseline at week 52 were observed in overall total mood disturbance scores of the POMSb in the taranabant 2-and 4-mg groups (Supplementary  Table S9 ). However, the changes in the Confusion-Bewilderment domain scores in the 4-mg group reflected a deterioration from baseline at week 52. There were no differences between taranabant groups and placebo in total mood disturbance scores or any of the domains from weeks 52 to 104 in patients who completed year 1 and entered year 2.
All treatment groups had deterioration from baseline in PHQ-9 scores at week 52, with the 4-mg group experiencing a greatest worsening (Supplementary Table S10 ). There were no differences from weeks 52 to 104 in patients who completed year 1 and entered year 2 on the same treatment.
The incidences of laboratory adverse experiences were low and generally comparable among the treatment groups in years 1 and 2 (Table 3) . No serious laboratory adverse experiences were reported in this study. There were no clinically relevant changes in heart rate or QTc interval in any of the treatment groups (data not shown).
Discussion
This study in obese and overweight patients showed that treatment with taranabant 2-and 4-mg resulted in statistically significant and clinically meaningful weight loss relative to placebo, which was sustained for 2 years.
A modest incremental weight loss efficacy was observed with taranabant at doses 42 mg. The placebo-subtracted weight loss observed with taranabant 4 mg was approximately 23 and 24% greater than that observed with taranabant 2 mg at the 1-and 2-year time points, respectively (percentages based on placebo-subtracted least-squares mean weight loss). Similarly, the weight loss efficacy of taranabant 6 mg was approximately 19% greater than that observed with 4 mg taranabant at 1 year. The modest increase in efficacy observed with the 4-and 6-mg doses in this study compared with the 2 mg dose, in conjunction with increased incidences of adverse experiences with the 4-and 6-mg doses relative to the 2-mg dose, led to the discontinuation of the 4-and 6-mg doses. These data also suggest that the higher doses had approached the maximum weight loss effect of taranabant.
Although head-to-head studies would be required for accurate comparison, it is nonetheless worthwhile to place the magnitude of weight loss associated with treatment with taranabant into context along with other centrally acting weight loss medications that have been studied in large clinical trials. The magnitude and time course of the weight loss observed with taranabant 2 mg at 1 year was comparable to the 1-year weight loss efficacy that was reported in clinical trials with 20 mg of the CB1R inverse agonist, rimonabant, [23] [24] [25] [26] and 10-20 mg of the serotonin and noradrenaline reuptake inhibitor, sibutramine. [27] [28] [29] [30] [31] For example, in the meta-analyses of weight loss studies, 31 compared with placebo, 10-20-mg sibutramine reduces body weight from baseline by 4.2 kg (3.6 to 4.7 kg) and 20-mg rimonabant reduces weight body weight from baseline by 4.7 kg (4.1 to 5.3 kg). On the basis of the data presented in this paper and this meta-analysis of rimonabant, it might be concluded that the CB1R mechanism, although capable of producing clinically meaningful weight loss, is not capable of producing double-digit weight loss as a monotherapy. The observed weight regain of patients who were downdosed from taranabant 6 mg to placebo compared with the weight regain observed in those down-dosed to taranabant 2 mg or those maintained on a stable dose of taranabant showed that, as expected, continued therapy with taranabant was necessary to maintain weight loss. The tendency for weight regain and the requirement for continued drug treatment to maintain weight loss has been observed in clinical trials with other drugs used for weight loss with similar (rimonabant) [23] [24] [25] [26] and different (sibutramine and the intestinal lipase inhibitor orlistat) 27,32 mechanisms of action.
The observed improvements in metabolic measures (WC, TG, HDL-C, fasting serum insulin and insulin sensitivity) and the decrease in the percentage of patients who meet criteria for the MS are consistent with the decrease in body weight and body fat observed with taranabant and are also consistent with the effects reported in clinical studies with rimonabant. [23] [24] [25] [26] These changes suggest that treatment with taranabant 2 and 4 mg might be associated with improvements in cardiometabolic risk. [33] [34] [35] [36] It has been hypothesized that CB1R inverse agonists exert an effect directly on adipocytes, hepatocytes, pancreatic islets and skeletal muscle to mediate metabolic effects. 37 Using a regression modeling approach, it has been reported that as much as 57% of the placebo-subtracted effects of 20-mg rimonabant on HDL-C and HbA1c were independent of weight loss and consistent with direct peripheral metabolic effects of rimonabant. 38 Using a similar regression modeling approach in this study, weight loss-independent effects of taranabant on HDL-C and QUICKI were observed. However, conclusive evidence for the contribution of peripherally located CB1R to in vivo efficacy of CB1R inverse antagonists is lacking, 39 and statistical analysis alone is not conclusive evidence of a weight-independent effect. 40 To show a weight-independent effect, a study design that included a treatment group that avoided weight loss by High-dose taranabant LJ Aronne et al adjusting energy intake or that involved comparison to a drug that had no effects beyond weight reduction would be required. The safety profile of taranabant was characterized by the increased incidences of adverse experiences classified in the gastrointestinal, psychiatric, nervous, cutaneous and vascular organ systems compared with placebo. In general, adverse experiences observed with taranabant were mild to moderate in intensity.
Gastrointestinal-related adverse experiences, including nausea, vomiting and diarrhea, were very common, especially in the first 2-3 months of treatment, but led to relatively few discontinuations. Gastrointestinal-related adverse experiences are consistent with the localization of CB1R on enteric neurons and in the hindbrain.
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CB1Rs are highly expressed in the central nervous system and adverse experiences in this organ system were prespecified for analysis. Adverse experiences in the dizziness, sedation and syncope groupings were generally higher in the taranabant 4-and 6-mg groups compared with the placebo group. In general, nervous system-related adverse experiences did not lead to discontinuation from study drug, and sensory grouping nervous system adverse experiences did not notably increase over time.
Psychiatric-related adverse experiences observed in this study included a range of reports of dysphoric states, including an increased incidence of affect lability, depression, anxiety, aggression, anger and suicidal ideation. CB1Rs are widely expressed in brain pathways involved in mood regulation, including the limbic system and prefrontal cortex. 10, [42] [43] [44] Alterations in CB1R signaling in those anatomic regions that may be associated with the treatment with taranabant provide a plausible mechanism for the observed increase in reports of adverse experiences related to dysphoric states in this study. Psychiatric-related adverse experiences were dose related and none of the doses used in this study was devoid of psychiatric-related adverse experiences when incidences were compared with placebo. It is noteworthy that increased incidences of these adverse experiences were also observed in studies with lower doses of taranabant (0.5-and 1.0-mg doses). 45, 46 The observed dose-response relationship between weight loss and incidence of psychiatric adverse experiences is consistent with these adverse experiences being mechanism based. Moreover, the increased incidence of psychiatric adverse experiences reported in the published rimonabant studies [23] [24] [25] [26] further supports the hypothesis that these adverse experiences are mechanism based. A strategy that has been used to augment the modest weight lose efficacy of existing antiobesity monotherapies is that of combination therapy. However, because of the lack of an adequate therapeutic window and concern for patient safety outside of the clinical trial setting, there does not seem to be a clear path forward for combining taranabant with other agents. For example, it is unlikely that addition of an antidepressant that itself is associated with weight loss (for example, Wellbutrin) to a CB1R inverse agonist would mitigate the risk of psychiatric adverse experiences to an extent that would significantly change the risk-benefit assessment of these compounds. Nor are there preclinical or clinical data to support a physiological rationale for the notion that a drug, such as phentermine, would mitigate the psychiatric adverse event profile of a CB1R inverse antagonist. On the other hand, some preclinical studies suggest that sub-therapeutic doses of CB1R inverse agonists in combination with other agents might prove to be a viable therapeutic strategy. [47] [48] [49] The clinical effect of the adverse experiences of hyperhidrosis, pruritus, flushing and hot flush were also dose related but more prominent in the 6-mg group. The clinical implications of these adverse experiences were, in general, modest based on their relatively low incidence, limited duration and infrequent need for patient discontinuation. Expression of CB1Rs in human skin 50 may be related to the adverse experiences of hyperhidrosis and pruritus. The adverse experiences of flushing and hot flush occurred predominantly in perimenopausal women and were reported less frequently by men. The mechanism underlying the flushing and hot flush adverse experiences is unclear.
The incidences of clinical adverse experiences in the taranabant 2-and 4-mg groups in year 2 were numerically lower when compared with year 1. These data are consistent with a 'survivor' effect in which patients who tolerated 52 weeks of taranabant therapy were less likely to experience adverse experiences during year 2. In general, the safety profile of taranabant 2 and 4 mg did not change meaningfully between years 1 and 2.
Despite the results reported in this study, suspension of rimonabant marketing in 2008 and the subsequent discontinuation of several other CB1R inverse antagonist development programs, it may be premature to abandon all efforts at antiobesity drug development that targets the CB1R. Several methods have been suggested that might circumvent the psychiatric side effects of CB1R antagonists. 51 Both taranabant and rimonabant 52 can exert an effect as CB1R inverse agonists and it is possible that neutral antagonists might not have the same behavioral liabilities. Similarly, it has been suggested that peripherally acting CB1R neutral antagonists or inverse agonists might provide another means of circumventing those side effects. 53, 54 Identification of CB1R antagonists with an improved side-effect profile, which could be used as monotherapy or combination therapy, still remains a relevant therapeutic goal.
